Clinical features of 216 Italian patients with NAFLD subdivided according to the p.Ala736Val <i>TMPRSS6</i> status.

<p>(): % values; BMI: body mass index; Hb: hemoglobin concentration; MCV mean corpuscular volume;</p>°<p>evaluated in cases negative for the beta-thalassemia trait (72 Ala/Ala, 91 Ala/Val, 31 Val/Val);</p>*<p>p<0.05 for Val/Val vs. Ala/Ala and Ala/Val (recessive model).</p

Relationship between clinical and genetic variables considered in the study with hepatic iron accumulation in 216 patients with NAFLD (univariate analysis).

<p>ALT: alanine aminotransferases; BMI: body mass index; CRP: C reactive protein; TS%: transferrin saturation %; <i>HFE</i> genotypes at risk: p.Cys282Tyr positive and p.His63Asp/His63Asp.</p

Clinical features associated with presence of NASH at baseline evaluation.

<p>Clinical features associated with presence of NASH at baseline evaluation.</p

Independent determinants of hepatic iron accumulation in 216 patients with NAFLD at multivariate logistic regression analysis.

<p>95% c.i.: 95% confidence interval; <i>HFE</i> genotypes at risk: p.Cys282Tyr positive and p.His63Asp/His63Asp.</p><p>In this model, the effect of the p.Ala736Val <i>TMPRSS6</i> variant was adjusted for age, gender, BMI and the other genetic factors.</p

Clinical features associated with fibrosis progression at baseline and follow-up evaluation in 108 patients with NAFLD without F4 fibrosis at baseline.

<p>Clinical features associated with fibrosis progression at baseline and follow-up evaluation in 108 patients with NAFLD without F4 fibrosis at baseline.</p

Independent predictors of FPR in 118 Italian patients with NAFLD (including 10 with F4 fibrosis at baseline).

<p>Independent predictors of FPR in 118 Italian patients with NAFLD (including 10 with F4 fibrosis at baseline).</p

Frequency distribution of genetic factors influencing iron metabolism in patients with and without hepatic iron accumulation.

<p>Patients positive for the beta-thalassemia trait were classified as “Beta-trait”, next if negative for “Beta-trait” and positive for <i>HFE</i> genotypes at risk as “HFE at risk”, and among the remaining patients those homozygous for the 736V/V TMPSS6 as “736VV”, and the rest as “none”.</p

Demographic, clinical, and genetic features of 216 Italian patients with NAFLD with available re-evaluation of histological siderosis and of 271 healthy controls with normal iron parameters, liver function tests, and metabolic parameters.

<p>(): % values; BMI: body mass index; Hb: hemoglobin concentration; TS%: transferrin saturation %; wt: wild-type variant;</p>*<p>p<0.05 vs. healthy controls;</p>∧<p>beta-thalassemia trait was a <i>criterium</i> for exclusion from blood donation.</p

Effect of <i>TMPRSS6</i> p.A736V genotype on hepcidin levels (hepcidin <3 nM, median value, panel A) and the hepcidin/ferritin ratio (panel B) in 55 patients with NAFLD (25.5% of the whole series).

<p>Effect of <i>TMPRSS6</i> p.A736V genotype on hepcidin levels (hepcidin <3 nM, median value, panel A) and the hepcidin/ferritin ratio (panel B) in 55 patients with NAFLD (25.5% of the whole series).</p

Clinical features of 118 Italian patients with NAFLD, who underwent a follow-up liver biopsy.

<p>Clinical features of 118 Italian patients with NAFLD, who underwent a follow-up liver biopsy.</p